

Heike L Rittner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9511231/publications.pdf>

Version: 2024-02-01

93
papers

4,660
citations

81900
39
h-index

106344
65
g-index

114
all docs

114
docs citations

114
times ranked

4676
citing authors

#	ARTICLE	IF	CITATIONS
1	Substance P Serum Degradation in Complex Regional Pain Syndrome – Another Piece of the Puzzle?. <i>Journal of Pain</i> , 2022, 23, 501-507.	1.4	5
2	Homeostatic calcium fluxes, ER calcium release, SOCE, and calcium oscillations in cultured astrocytes are interlinked by a small calcium toolkit. <i>Cell Calcium</i> , 2022, 101, 102515.	2.4	7
3	Pain, disability, and lifestyle: Patients with complex regional pain syndrome compared to chronic musculoskeletal pain – A retrospective analysis. <i>European Journal of Pain</i> , 2022, 26, 719-728.	2.8	4
4	Transient hypoalgesia after COVID-19 infection. <i>Pain Reports</i> , 2022, 7, e990.	2.7	4
5	Microvascular Barrier Protection by microRNA-183 via FoxO1 Repression: A Pathway Disturbed in Neuropathy and Complex Regional Pain Syndrome. <i>Journal of Pain</i> , 2022, 23, 967-980.	1.4	8
6	MicroRNA-21-5p functions via RECK/MMP9 as a proalgesic regulator of the blood nerve barrier in nerve injury. <i>Annals of the New York Academy of Sciences</i> , 2022, 1515, 184-195.	3.8	6
7	Stabilization of Delphinidin in Complex with Sulfobutylether- β -Cyclodextrin Allows for Antinociception in Inflammatory Pain. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1260-1279.	5.4	9
8	Selective blood-nerve barrier leakiness with claudin-1 and vessel-associated macrophage loss in diabetic polyneuropathy. <i>Journal of Molecular Medicine</i> , 2021, 99, 1237-1250.	3.9	14
9	Complex regional pain syndrome: role of contralateral sensitisation. <i>British Journal of Anaesthesia</i> , 2021, 127, e1-e3.	3.4	11
10	Netrin-1 as a Multitarget Barrier Stabilizer in the Peripheral Nerve after Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10090.	4.1	3
11	Impaired psychological well-being of healthcare workers in a German department of anesthesiology is independent of immediate SARS-CoV-2 exposure - a longitudinal observational study. <i>GMS German Medical Science</i> , 2021, 19, Doc11.	2.7	0
12	Regional Differences in Tight Junction Protein Expression in the Blood – DRG Barrier and Their Alterations after Nerve Traumatic Injury in Rats. <i>International Journal of Molecular Sciences</i> , 2020, 21, 270.	4.1	18
13	Clinical phenotypes and classification algorithm for complex regional pain syndrome. <i>Neurology</i> , 2020, 94, e357-e367.	1.1	35
14	D-4F, an ApoA-I mimetic peptide ameliorating TRPA1-mediated nocifensive behaviour in a model of neurogenic inflammation. <i>Molecular Pain</i> , 2020, 16, 174480692090384.	2.1	11
15	Characteristics of the nerve barrier and the blood dorsal root ganglion barrier in health and disease. <i>Experimental Neurology</i> , 2020, 327, 113244.	4.1	45
16	Sensitivity and specificity of cerebrospinal fluid CXCL13 for diagnosing Lyme neuroborreliosis - a study on 1410 patients and review of the literature. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116843.	0.6	9
17	Pain Control by Targeting Oxidized Phospholipids: Functions, Mechanisms, Perspectives. <i>Frontiers in Endocrinology</i> , 2020, 11, 613868.	3.5	4
18	Therapeutic Drug Monitoring of Antidepressants for the Treatment of Chronic Musculoskeletal Pain With and Without Depression. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 893-901.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Immune System, Pain and Analgesia. , 2020, , 385-397.		1
20	Antinociceptive modulation by the adhesion GPCR C1RL promotes mechanosensory signal discrimination. ELife, 2020, 9, .	6.0	15
21	The serum protease networkâ€”one key to understand complex regional pain syndrome pathophysiology. Pain, 2019, 160, 1402-1409.	4.2	14
22	What is normal trauma healing and what is complex regional pain syndrome I? An analysis of clinical and experimental biomarkers. Pain, 2019, 160, 2278-2289.	4.2	35
23	Tissue plasminogen activator and neuropathy open the blood-nerve barrier with upregulation of microRNA-155-5p in male rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1160-1169.	3.8	16
24	Antinociception by the antiâ€”oxidized phospholipid antibody <sc>E06</sc>. British Journal of Pharmacology, 2018, 175, 2940-2955.	5.4	12
25	Role of curcumin in the management of pathological pain. Phytomedicine, 2018, 48, 129-140.	5.3	66
26	Opioids and the immune system â€” friend or foe. British Journal of Pharmacology, 2018, 175, 2717-2725.	5.4	301
27	Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain. Redox Biology, 2018, 14, 391-397.	9.0	74
28	Quantitative and Microstructural Changes of the Blood-Nerve Barrier in Peripheral Neuropathy. Frontiers in Neuroscience, 2018, 12, 936.	2.8	29
29	NaV1.9 Potentiates Oxidized Phospholipid-Induced TRP Responses Only under Inflammatory Conditions. Frontiers in Molecular Neuroscience, 2018, 11, 7.	2.9	9
30	A Novel Approach for the Control of Inflammatory Pain: Prostaglandin E2 Complexation by Randomly Methylated Î²-Cyclodextrins. Anesthesia and Analgesia, 2017, 124, 675-685.	2.2	17
31	The Role of Spinal GABAB Receptors in Cancer-Induced Bone Pain in Rats. Journal of Pain, 2017, 18, 933-946.	1.4	33
32	Barrier function in the peripheral and central nervous systemâ€”a review. Pflügers Archiv European Journal of Physiology, 2017, 469, 123-134.	2.8	216
33	Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain, 2017, 158, 2340-2353.	4.2	116
34	Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation. Scientific Reports, 2017, 7, 5447.	3.3	53
35	Bloodâ€”spinal cord barrier breakdown and pericyte deficiency in peripheral neuropathy. Annals of the New York Academy of Sciences, 2017, 1405, 71-88.	3.8	44
36	Peripheral Interaction of Resolvin D1 and E1 with Opioid Receptor Antagonists for Antinociception in Inflammatory Pain in Rats. Frontiers in Molecular Neuroscience, 2017, 10, 242.	2.9	30

#	ARTICLE	IF	CITATIONS
37	Functional and structural characterization of axonal opioid receptors as targets for analgesia. <i>Molecular Pain</i> , 2016, 12, 174480691662873.	2.1	22
38	Increased cutaneous miR-let-7d expression correlates with small nerve fiber pathology in patients with fibromyalgia syndrome. <i>Pain</i> , 2016, 157, 2493-2503.	4.2	58
39	Analgesic drug delivery via recombinant tissue plasminogen activator and microRNA-183-triggered opening of the blood-nerve barrier. <i>Biomaterials</i> , 2016, 82, 20-33.	11.4	28
40	Reduced dermal nerve fiber diameter in skin biopsies of patients with fibromyalgia. <i>Pain</i> , 2015, 156, 2319-2325.	4.2	105
41	Differential Transcriptional Profiling of Damaged and Intact Adjacent Dorsal Root Ganglia Neurons in Neuropathic Pain. <i>PLoS ONE</i> , 2015, 10, e0123342.	2.5	41
42	Redox-Sensitive Structure and Function of the First Extracellular Loop of the Cellâ€Cell Contact Protein Claudin-1: Lessons from Molecular Structure to Animals. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1-14.	5.4	27
43	CXCL10 Controls Inflammatory Pain via Opioid Peptide-Containing Macrophages in Electroacupuncture. <i>PLoS ONE</i> , 2014, 9, e94696.	2.5	56
44	Toll like Receptor (TLR)-4 as a Regulator of Peripheral Endogenous Opioid-Mediated Analgesia in Inflammation. <i>Molecular Pain</i> , 2014, 10, 1744-8069-10-10.	2.1	51
45	Safety, efficacy, and molecular mechanism of claudin-1-specific peptides to enhance bloodâ€nerveâ€barrier permeability. <i>Journal of Controlled Release</i> , 2014, 185, 88-98.	9.9	37
46	Thoracic epidural anesthesia decreases endotoxin-induced endothelial injury. <i>BMC Anesthesiology</i> , 2014, 14, 23.	1.8	12
47	The Molecular Link Between C-C-Chemokine Ligand 2-Induced Leukocyte Recruitment and Hyperalgesia. <i>Journal of Pain</i> , 2013, 14, 897-910.	1.4	20
48	Longâ€term antinociception by electroacupuncture is mediated via peripheral opioid receptors in freeâ€moving rats with inflammatory hyperalgesia. <i>European Journal of Pain</i> , 2013, 17, 1447-1457.	2.8	23
49	microRNAs in nociceptive circuits as predictors of future clinical applications. <i>Frontiers in Molecular Neuroscience</i> , 2013, 6, 33.	2.9	70
50	The Connection of Monocytes and Reactive Oxygen Species in Pain. <i>PLoS ONE</i> , 2013, 8, e63564.	2.5	63
51	Transient opening of the perineurial barrier for analgesic drug delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2018-27.	7.1	87
52	A Peptidomimetic Tight Junction Modulator To Improve Regional Analgesia. <i>Molecular Pharmaceutics</i> , 2012, 9, 1785-1794.	4.6	44
53	Modulation of tight junction proteins in the perineurium for regional pain control. <i>Annals of the New York Academy of Sciences</i> , 2012, 1257, 199-206.	3.8	21
54	Modulation of Tight Junction Proteins in the Perineurium to Facilitate Peripheral Opioid Analgesia. <i>Anesthesiology</i> , 2012, 116, 1323-1334.	2.5	25

#	ARTICLE	IF	CITATIONS
55	Recruitment of opioid peptide-containing neutrophils is independent of formyl peptide receptors. <i>Journal of Neuroimmunology</i> , 2011, 230, 65-73.	2.3	4
56	Immunosuppressive Effects of Opioidsâ€”Clinical Relevance. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 490-502.	4.1	64
57	The clinical (ir)relevance of opioid-induced immune suppression. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 588-592.	2.0	36
58	Leukocytes as Mediators of Pain and Analgesia. <i>NeuroImmune Biology</i> , 2010, , 237-250.	0.2	1
59	Mycobacteria Attenuate Nociceptive Responses by Formyl Peptide Receptor Triggered Opioid Peptide Release from Neutrophils. <i>PLoS Pathogens</i> , 2009, 5, e1000362.	4.7	79
60	Antinociception by neutrophil-derived opioid peptides in noninflamed tissueâ€”Role of hypertonicity and the perineurium. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 548-557.	4.1	31
61	Peripheral Non-Viral MIDGE Vector-Driven Delivery of δ^2 -Endorphin in Inflammatory Pain. <i>Molecular Pain</i> , 2009, 5, 1744-8069-5-72.	2.1	25
62	Immune cellâ€”derived opioids protect against neuropathic pain in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 278-86.	8.2	68
63	Immune cellâ€”derived opioids protect against neuropathic pain in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 1051-1051.	8.2	74
64	The other side of the medal: How chemokines promote analgesia. <i>Neuroscience Letters</i> , 2008, 437, 203-208.	2.1	24
65	Pain and the immune system. <i>British Journal of Anaesthesia</i> , 2008, 101, 40-44.	3.4	91
66	Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. <i>Journal of Clinical Investigation</i> , 2008, 118, 1065-73.	8.2	105
67	CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 1021-1032.	4.1	53
68	Lymphocytes upregulate signal sequence-encoding proopiomelanocortin mRNA and beta-endorphin during painful inflammation in vivo. <i>Journal of Neuroimmunology</i> , 2007, 183, 133-145.	2.3	61
69	Leukocytes as mediators of pain and analgesia. <i>Current Rheumatology Reports</i> , 2007, 9, 503-510.	4.7	31
70	Neurokinin-1 Receptor Antagonists Inhibit the Recruitment of Opioid-containing Leukocytes and Impair Peripheral Antinociception. <i>Anesthesiology</i> , 2007, 107, 1009-1017.	2.5	35
71	Interleukin-1 beta contributes to the upregulation of kappa opioid receptor mrna in dorsal root ganglia in response to peripheral inflammation. <i>Neuroscience</i> , 2006, 141, 989-998.	2.3	60
72	Comment on â€œNeutrophils: are they hyperalgesic or anti-hyperalgesic?â€• <i>Journal of Leukocyte Biology</i> , 2006, 80, 729-730.	3.3	2

#	ARTICLE	IF	CITATIONS
73	Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. Journal of Leukocyte Biology, 2006, 79, 1022-1032.	3.3	81
74	Pain control by CXCR2 ligands through Ca ²⁺ -regulated release of opioid peptides from polymorphonuclear cells. FASEB Journal, 2006, 20, 2627-2629.	0.5	110
75	Peripheral Antinociceptive Effects of Exogenous and Immune Cell-Derived Endomorphins in Prolonged Inflammatory Pain. Journal of Neuroscience, 2006, 26, 4350-4358.	3.6	73
76	Involvement of cytokines, chemokines and adhesion molecules in opioid analgesia. European Journal of Pain, 2005, 9, 109-112.	2.8	35
77	Leukocytes in the regulation of pain and analgesia. Journal of Leukocyte Biology, 2005, 78, 1215-1222.	3.3	104
78	Selectins and integrins but not platelet-endothelial cell adhesion molecule-1 regulate opioid inhibition of inflammatory pain. British Journal of Pharmacology, 2004, 142, 772-780.	5.4	53
79	Endogenous peripheral antinociception in early inflammation is not limited by the number of opioid-containing leukocytes but by opioid receptor expression. Pain, 2004, 108, 67-75.	4.2	72
80	Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells. Pain, 2004, 112, 229-238.	4.2	115
81	Tissue Monocytes/Macrophages in Inflammation. Anesthesiology, 2004, 101, 204-211.	2.5	66
82	Mobilization of Opioid-containing Polymorphonuclear Cells by Hematopoietic Growth Factors and Influence on Inflammatory Pain. Anesthesiology, 2004, 100, 149-157.	2.5	57
83	Neurogenic painful inflammation. Current Opinion in Anaesthesiology, 2004, 17, 461-464.	2.0	7
84	Pro-algesic versus analgesic actions of immune cells. Current Opinion in Anaesthesiology, 2003, 16, 527-533.	2.0	26
85	Modulation of Peripheral Endogenous Opioid Analgesia by Central Afferent Blockade. Anesthesiology, 2003, 98, 195-202.	2.5	46
86	Opioid Control of Inflammatory Pain Regulated by Intercellular Adhesion Molecule-1. Journal of Neuroscience, 2002, 22, 5588-5596.	3.6	111
87	Opioid Peptide-expressing Leukocytes. Anesthesiology, 2001, 95, 500-508.	2.5	206
88	Anti-Psoriatic Drug Anthralin Activates JNK via Lipid Peroxidation: Mononuclear Cells are More Sensitive than Keratinocytes. Journal of Investigative Dermatology, 2000, 114, 688-692.	0.7	24
89	Tissue-Destructive Macrophages in Giant Cell Arteritis. Circulation Research, 1999, 84, 1050-1058.	4.5	128
90	Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. Journal of Clinical Investigation, 1999, 103, 1007-1013.	8.2	187

#	ARTICLE	IF	CITATIONS
91	Developmental patterns of serum 3 β -androstanediol glucuronide. Journal of Endocrinological Investigation, 1997, 20, 138-143.	3.3	3
92	Multiple Mechanisms Support Oligoclonal T Cell Expansion in Rheumatoid Synovitis. Molecular Medicine, 1997, 3, 452-465.	4.4	39
93	Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.. Journal of Clinical Investigation, 1997, 99, 2842-2850.	8.2	117